Skip to content

A prospective, multicenter, randomized, controlled clinical study on the efficacy and safety of a dual therapy with amoxicillin-clavulanate and minocycline-clavulanate for the eradication of Helicobacter pylori.

A prospective, multicenter, randomized, controlled clinical study on the efficacy and safety of a dual therapy with amoxicillin-clavulanate and minocycline-clavulanate for the eradication of Helicobacter pylori. - A clinical study on the efficacy and safety of a dual therapy with amoxicillin-clavulanate and minocycline-clavulanate for the eradication of Helicobacter pylori.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092848
Enrollment
Unknown
Registered
2024-11-25
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

A group:Minocyclin (100mg each time, bid day)+Cefpodoxime (20 mg each time, qd) for 14 days.
B group:Amoxicillin (1000mg each time, tid a day)+Cefpodoxime (20 mg each time, bid) for 14 days.

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients, aged 18 to 80 years; 2. Before treatment, no tetracycline, minocycline, doxycycline, or amoxicillin was used to eradicate Helicobacter pylori, patients who did not take antibiotics, bismuth, and traditional Chinese medicine 4 weeks before treatment, and patients who took PPI, H2 receptor antagonists, and other drugs 2 weeks before treatment; 3. Hp-positive was diagnosed by C13 or C14-urea breath test and rapid urease test; 4. Informed and agreed to participate in the study, patients with complete medical records and follow-up records.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe primary diseases of the heart, lungs, kidneys, liver, and blood system, as well as those with low immunity; 2. Patients with drug allergy contraindications; 3. Persons with mental illness or communication difficulties; 4. Pregnancy, lactation; 5. Patients with organic diseases such as gastrointestinal tumor and gastrointestinal hemorrhage.

Design outcomes

Primary

MeasureTime frame
Eradication rate;

Secondary

MeasureTime frame
Degree of clinical symptom remission;Adverse reaction;

Countries

China

Contacts

Public ContactXueping Huang

Fujian Provincial Hospital

13799371368@139.com+86 157 5081 9302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026